Daniel C. Sevin

Daniel C. Sevin

Auto-generated profile, based on publicly available information

Daniel C. Sevin

Target Discovery GlaxoSmithKline 69117 Heidelberg Germany

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2022 in Metabolic Engineering
Verified
Journal Article
Closed access
GBGianmarco Barberi
Gianmarco Barberi
ABAntonio Benedetti
Antonio Benedetti
PDPaloma Diaz-Fernandez
Paloma Diaz-Fernandez
DSDaniel C. Sévin
Daniel C. Sévin
JVJohanna Vappiani
Johanna Vappiani
Pierantonio FaccoPierantonio Facco
Pierantonio Facco

9 October 2024 in AIChE Journal
Verified
Journal Article
Open access
GBGianmarco Barberi
Gianmarco Barberi
ABAntonio Benedetti
Antonio Benedetti
PDPaloma Diaz‐Fernandez
Paloma Diaz‐Fernandez
DSDaniel C. Sévin
Daniel C. Sévin
JVJohanna Vappiani
Johanna Vappiani
Pierantonio FaccoPierantonio Facco
Pierantonio Facco
The identification of highly productive cell lines is crucial in the development of bioprocesses for the production of therapeutic monoclonal antibodies (mAbs). Metabolomics data provide valuable information for cell line selection and allow the study of the relationship with mAb productivity and product quality attributes. We propose a novel robust machine learning procedure which, exploiting dynamic metabolomic data from the Ambr®15 scale, supports the selection of highly productive cell lines during biopharmaceutical bioprocess development and scale‐up. The metabolomic profiles dynamics allows to identify the cell lines with high productivity, already in the early stages of experimentation, and the biomarkers that are the most related to mAb productivity, finding at the same time the key metabolic pathways for discriminating mAb productivity. Specifically, tricarboxylic acid cycle pathways are predominant in the early stages of the cultivation, while amino and nucleotide sugar pathways influence in the late stages of the culture.

3 January 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
SWSander Wuyts
Sander Wuyts
RARenato Alves
Renato Alves
MZMaria Zimmermann-Kogadeeva
Maria Zimmermann-Kogadeeva
SNSuguru Nishijima
Suguru Nishijima
SBSonja Blasche
Sonja Blasche
PBPeer Bork
Peer Bork
Multi-omics analyses are increasingly employed in microbiome studies to obtain a holistic view of molecular changes occurring within microbial communities exposed to different conditions. However, it is not always clear to what extent each omics data type contributes to our understanding of the community dynamics and whether they are concordant with each other. Here we map the molecular response of a synthetic community of 32 human gut bacteria to three non-antibiotic drugs by using five omics layers, namely 16S rRNA gene profiling, metagenomics, metatranscriptomics, metaproteomics, and metabolomics. Using this controlled setting, we find that all omics methods with species resolution in their readouts are highly consistent in estimating relative species abundances across conditions. Furthermore, different omics methods complement each other in their ability to capture functional changes in response to the drug perturbations. For example, while nearly all omics data types captured that the antipsychotic drug chlorpromazine selectively inhibits Bacteroidota representatives in the community, the metatranscriptome and metaproteome suggested that the drug induces stress responses related to protein quality control and metabolomics revealed a decrease in polysaccharide uptake, likely caused by Bacteroidota depletion. Taken together, our study provides insights into how multi-omics datasets can be utilised to reveal complex molecular responses to external perturbations in microbial communities.

18 October 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
SKSascha Knecht
Sascha Knecht
MKMathias Kalxdorf
Mathias Kalxdorf
JKJohanna Korbeń
Johanna Korbeń
TMToby Mathieson
Toby Mathieson
DSDaniel C. Sevin
Daniel C. Sevin
MBMarcus Bantscheff
Marcus Bantscheff
Adverse drug reactions (ADRs) contribute significantly to late-stage attrition in drug discovery due to their unpredictability and enigmatic underlying mechanisms. Here we applied mass spectrometry-based proteomics to assess the effects of 46 approved or retracted drugs with various levels of concerns for drug-induced liver injury and annotated for mitochondrial mechanisms, along with 8 tool compounds, on the secretome of a hepatocyte liver model. We observed distinct clusters of non-canonical secretion, and intracellular thermal proteome profiling linked dysregulated mechanisms to extracellular markers. Functional follow-up confirmed lysosomal alterations by cationic-amphiphilic drugs, connected damage of the respiratory chain to Rab7-dependent secretion of mitochondrial proteins, and linked drug-induced endoplasmic reticulum stress to reduced basal secretion. Perturbation of sphingolipid biosynthesis pathways specifically induced secretion of the cargo sorting protein SDF4 whilst suppressing secretion of its cargo proteins. Thermal stability changes of clusters of membrane proteins in distinct subcellular compartments suggest local accumulation as important driver for unexpected drug effects through direct and indirect interactions.

24 January 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
KSKsenija Radic Shechter
Ksenija Radic Shechter
EKEleni Kafkia
Eleni Kafkia
KZKatharina Zirngibl
Katharina Zirngibl
SGSylwia Gawrzak
Sylwia Gawrzak
AAAshna Alladin
Ashna Alladin
MJMartin Jechlinger
Martin Jechlinger
Tumor relapse is responsible for most breast cancer related deaths 1,2 . The disease recurrence stems from treatment refractory cancer cells that persist as minimal residual disease (MRD) for years following initial therapy 3 . Yet, the molecular characteristics defining the malignancy of MRD remain elusive due to difficulties in observing these rare cells in patients or in model organisms. Here, we use a tractable organoid system and multi-omics analysis to show that the dormant MRD cells retain metabolic peculiarities reminiscent of the tumor state. While the MRD cells were distinct from both normal and tumor cells at a global transcriptomic level, their metabolomic and lipidomic profile markedly resembled that of the tumor state. The MRD cells particularly exhibited a de-regulated urea cycle and elevated glycolysis. We find the latter being crucial for their survival and could be selectively targeted using a small molecule inhibitor of glycolytic activity. We validated these metabolic peculiarities of the MRD cells in corresponding tissues obtained from the mouse model as well as in transcriptomic data from patients following neo-adjuvant therapy. Together, our results show that the treatment surviving MRD cells retain features of the tumor state over an extended period suggestive of an oncogenic memory. In accord, we found striking similarity in DNA methylation profiles between the tumor and the MRD cells. The distinction of MRD from normal breast cells comes as a surprise, considering their phenotypic similarity with regards to proliferation and polarized epithelial organization. The metabolic aberrances of the MRD cells offer a therapeutic opportunity towards tackling emergence of breast tumor recurrence in post-treatment care.